The Last Chance To Be First-To-Market, Is Right Now, With Psych-a-delics

On November 3rd, 2020, Oregon made history by becoming the first U.S. state to allow the use of the psych-e-delic dr-ug psi-lo-cybin in supervised facilities when voters approved Measure 109… ⁽⁷⁾

The state’s program won’t be up and running until January 2023, and there is a lot of work to do… ⁽⁷⁾

But get this…

There is only publicly traded psych-e-delic company with legal psych-e-delic retreat experience and a strong connection to Oregon.

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFD) is the only publicly-traded company in Oregon: ⁽³⁾

…Founded by an Oregonian.

…To host a psych-e-delic retreat in Oregon.

…That has legal psi-lo-cybin operations in Jamaica.

When investors realize that Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFD) could be one of the best ways to participate in the psych-e-delic sector, there is no telling what could happen to the share price of this company.

With some predicting that the psych-e-delic industry in Oregon alone could quickly grow to $1 billion (8)– it won’t be long until savvy investors come looking for a way to play this market like they did the cann-a-bis stocks.

Silo Wellness Inc. is a true under-the-radar find with a very small market cap.

The market cap is one of the most important metrics that investors look at when deciding whether to invest in a company – a company’s market cap is the total number of its outstanding shares of stock multiplied by the current share price. ⁽⁹⁾

…And according to OTCMarkets.com, as of July 7th, 2022, the market cap of Silo Wellness Inc is only $249,624…⁽¹⁾

However, the market cap doesn’t always tell the whole story.

That’s why small market cap stocks move up fast.

In fact, when you check Silo Wellness Inc.’s price history on BarChart.com, you’ll see that on June 21, 2022, shares of (SILFD) traded as low as $.088. ⁽¹⁰⁾

Then just 9 business days later, on July 5th, on what appears to be very little volume, shares of (SILFD) reached over $.113 for a 28.41% move…⁽¹⁰⁾ (not bad for a few days)

Silo Wellness Inc shares moved 28.41% in 9 days. ⁽¹⁰⁾

And the S&P 500 moved a paltry 1.9% during the same period. ⁽¹¹⁾

Keep reading to see why Silo Wellness Inc. could be the most undervalued story of the decade…

In 1996 California became the first state in the U.S. to legalize cann-a-bis for medical use ⁽¹²⁾ – 10 years later, the cann-a-bis market was literally blazing up the charts and early investors were becoming filthy rich.

Once the cann-a-bis stocks started moving, they didn’t stop – and from 2016 to 2018 more gains were made in the cann-a-bis market than almost any other market in the same 2 year period… ⁽¹³⁾

You would have to agree that these moves were incredible… and probably life changing for some of those who got in early…
But forget about cann-a-bis stocks for now. Those days have come and gone..

In the U.S, the psych-e-delic dr-ug market is expected to reach $8.9 billion by 2029. ⁽⁶⁾

This is due to the increasing rates of mental health disorders that require psych-e-delic treatments and the increase in governments’ willingness to fund the treatments. ⁽⁶⁾

Savvy investors will start to notice the trend here. The anti-depressant dr-ug market is expected to hit $16 billion by 2023 and that legacy industry has been around since the 1950’s…

The psych-e-delic market is the next big thing as big dollars are beginning to pour into the industry… which is expected to reach $8.9 billion by 2029 — not bad for a brand new industry..

Which is why Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) needs to be at the top of your watchlist..

Bipartisan lawmakers in Congress introduced several drug policy reform amendments in a large-scale advocacy bill to the National Defense Authorization Act.⁽²⁰⁾

Banning federal employment discrimination against veterans who use marijuana, providing funding for studies on psych-e-delics’ therapeutic benefits, and allowing US Department of Veterans Affairs doctors to recommend medical cannabis to veterans are part of the proposals included in the amendments.⁽²⁰⁾

House Appropriations Committee leadership has taken a special interest in psych-e-delics research this year as they’ve crafted spending bills and reports to fund various federal agencies. ⁽²¹⁾

And one of the latest examples of that interest comes from a manager’s amendment to legislation covering the Department of Health and Human Services. ⁽²¹⁾

The newly added report language contains two sections addressing the therapeutic potential of psychedelics. ⁽²¹⁾

One broadly encourages research into the substances as potential treatment options for post-traumatic stress disorder and severe depression, while the other talks about psychedelics as a possible tool to combat conditions that commonly afflict military veterans. ⁽²¹⁾

The measures, adopted by the committee build on other existing drug policy reform provisions of the appropriations bill and report. ⁽²¹⁾

But the psych-e-delics language is a positive signal from the committee as far as reform advocates are concerned. ⁽²¹⁾

The state of Oregon is pursuing an alternative model in which trained facilitators licensed by the Oregon Health Authority will administer psi-lo-cybin. ⁽²²⁾

Clients seeking access to ‘psi-lo-cybin services’, as they are called in Oregon, need not have a medical diagnosis to participate. ⁽²²⁾

Because clinical-trial participants often report sustained feelings of wellbeing, some believe psi-lo-cybin services could help fill the current gap in preventative mental healthcare. ⁽²²⁾

Oregon is on track to become the first US state to roll out legal psi-lo-cybin, the psych-o-active substance found in “magic” mush-rooms starting in just a few months. ⁽¹⁶⁾

Will there be a state-by-state rollout like what is happening with cann-a-bis?

Or will the future of psych-e-delics be a pure pharma play?

Silo Wellness is the only public company with assets covering both options. ⁽¹⁵⁾

Silo Wellness recently announced plans to create a Psych-e-delic Pharmaceutical Manufacturing and Research Portfolio with a proposed acquisition of Dyscovry Science.

This was a very strategic move by Silo Wellness…

Dyscovry Science focuses on biosynthetic manufacturing of psi-lo-cybin and its derivatives targeting a physiological condition, irritable bowel syndrome. ⁽¹⁷⁾

With Dyscovry’s research collaboration with Canadian federal government research laboratories, Dyscovry intends to develop a biotechnological process for the production of psi-lo-cybin and its potentially novel molecule derivatives. ⁽¹⁷⁾

Dyscovry has embarked on the rigorous scientific investigation of enhanced biosynthesis of psi-lo-cybin as an alternative therapeutic option to both naturally occurring and chemically synthesized psi-lo-cybin. ⁽¹⁷⁾

This will not only allow for the future wide-scale production, but also fuel Dyscovry’s mission to unlock the potential for psi-lo-cybin in addressing a variety of disorders with the goal of developing safe, FDA and Health Canada approved therapies. ⁽¹⁷⁾

Let’s see why Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) could be one of those high potential companies by combining both business models

Silo Wellness Inc. is combining the booming demand for psych-e-delic retreat based healing with the biosynthetic manufacturing of psil-o-cybin for psych-e-delics-inspired medicines. ⁽¹⁵⁾

Silo Wellness is the only public company with assets covering both options. ⁽¹⁵⁾

Portfolio Breakout:
Jamaica Psych-e-delic Wellness Retreat ⁽¹⁵⁾
Flagship first-of-its-kind Jamaica wellness retreat

Conducting legal psi-lo-cybin-and 5-MeO-D-M-T-assisted retreats and mush-room and truffle cultivation workshops. ⁽¹⁵⁾
Silo Wellness held its inaugural psi-lo-cybin wellness retreat in Feb 2021. ⁽¹⁵⁾

Portfolio Breakout:
Oregon Nature-Based Psych-e-delic Ket-a-mine Retreat ⁽¹⁵⁾

The first legal psych-e-delic retreat ever conducted in the U.S.

In 2021, held legal, ket-a-mine-assisted wellness retreats in Oregon under the care of an Oregon physician.(15)
In November 2020, Oregon passed Measure 109 permitting licensed service providers to administer psi-lo-cybin in a facilitated setting. (15)

Portfolio Breakout:
Dyscovry Science* ⁽¹⁵⁾

Biosynthesis Partnership with Canadian Government with plans for:
Cost-Effective/Lower Impact API Manufacturing Alternative to Chemical Synthesis. ⁽¹⁵⁾
Patentable Molecular Cocktails and Chemical Derivatives. ⁽¹⁵⁾
IBS: While other companies only focus on mental health, gut health is where Silo Wellness Inc. will differentiate from other companies. ⁽¹⁵⁾
Controlled Substances DEL License. ⁽¹⁵⁾
University Partner for Trials. ⁽¹⁵⁾